SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.

Iro, MA; Snape, MD; Voysey, M; Jawad, S; Finn, A; Heath, PT; Bona, G; Esposito, S; Diez-Domingo, J; Prymula, R; et al. Iro, MA; Snape, MD; Voysey, M; Jawad, S; Finn, A; Heath, PT; Bona, G; Esposito, S; Diez-Domingo, J; Prymula, R; Odueyungbo, A; Toneatto, D; Dull, P; Pollard, AJ; European Men B Vaccine Study Group, (2017) Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. Vaccine, 35 (2). pp. 395-402. ISSN 1873-2518 https://doi.org/10.1016/j.vaccine.2016.11.009
SGUL Authors: Heath, Paul Trafford

[img] PDF Published Version
Restricted to Repository staff only
Available under License Creative Commons Attribution.

Download (834kB)

Abstract

BACKGROUND: 4CMenB is immunogenic in infants and toddlers. We assessed persistence of human complement serum bactericidal activity (hSBA) following a fourth dose administered at 12, 18 or 24months and characterised the antibody response to a fifth dose administered at 4years of age. METHODS: A phase 3, open label, multi-centre extension to a randomised controlled trial conducted in four countries (number of centres): Czech Republic (nineteen), Italy (four), Spain (four) and the United Kingdom (four). Four-year-old children who were either 4CMenB-naïve or had previously received a variety of 3-dose infant priming schedules and a booster vaccine as toddlers (follow-on group) were recruited. Venous blood samples were obtained to determine hSBA against four reference strains; acting as targets to assess immunity to each of the vaccine antigens, NadA (5/99), fHbp (H44/76), PorA (NZ98/254), and NHBA (M10713) at baseline (prior to vaccination, all participants) and one month following a dose of 4CMenB for all vaccine-naïve and follow-on participants primed with the 2, 3, 4 schedule, and a third of follow-on participants primed with a 2, 4, 6month schedule. RESULTS: At baseline (prior to vaccination), the proportion of participants (n=468) with hSBA titers⩾5 was similar across all followon groups: 89-100% against 5/99; 12-35% for H44/76; 8-12% for NZ98/254 and 53-80% for M10713 compared with 5%, 0%, 0%; and 60% respectively, for the vaccine-naïve controls (n=206). Following a dose of 4CMenB at 4years of age, this increased to 100% (5/99), 97-100% (H44/76), 80-95 % (NZ98/254) and 84-100% (M10713) (n=210), compared with 89%, 70%, 24%, and 76% respectively for vaccine-naïve controls (n=192). CONCLUSION: Waning of protective antibodies occurred 12-36months after toddler booster regardless of age at boost. This was least marked against target strains 5/99 and M10713. A robust memory response occurred after a booster dose given at 4years of age.

Item Type: Article
Additional Information: © 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Keywords: 4CMenB, MenW, Neisseria meningitidis, Reactogenicity, Toddler, Vaccine, 4CMenB, Neisseria meningitidis, Vaccine, Reactogenicity, MenW, Toddler, Virology, 06 Biological Sciences, 07 Agricultural And Veterinary Sciences, 11 Medical And Health Sciences
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Vaccine
ISSN: 1873-2518
Language: eng
Dates:
DateEvent
5 January 2017Published
30 November 2016Published Online
3 November 2016Accepted
Publisher License: Creative Commons: Attribution 4.0
PubMed ID: 27914744
Web of Science ID: WOS:000392892100029
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/108639
Publisher's version: https://doi.org/10.1016/j.vaccine.2016.11.009

Actions (login required)

Edit Item Edit Item